Telix Pharmaceuticals (ASX:TLX) has raised its full-year revenue guidance to between US$800 million and US$820 million following a solid third quarter marked by 53 per cent year-on-year revenue growth, reimbursement wins for Gozellix in the United States, and further expansion of its commercial footprint in Europe. …
Telix Pharmaceuticals lifts revenue guidance after strong third quarter performance
October 15, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 10 April
April 10, 2026 - - Podcast -
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News